Valuation: Positron Corporation

Market Cap 50.91M 44.49M 41.13M 38M 71.56M 4.89B 72.85M 490M 192M 2.39B 191M 187M 8.25B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 49.77M 43.5M 40.21M 37.15M 69.96M 4.78B 71.23M 480M 188M 2.34B 187M 183M 8.06B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.68%+6.18%-11.72%-20.22% 13.34B
+3.73%-11.73%+60.88%-0.52% 4.39B
-6.16%-8.55%+57.86%+96.72% 1.17B
-2.36%-0.16%-34.83%-61.90% 1.17B
-0.75%+2.22%-38.95%-47.19% 1.1B
+2.23%+1.93%-46.02% - 901M
-1.79%-11.17%+111.34%+112.07% 551M
+2.25%+12.17%+45.54% - 318M
+0.50%+3.54%-51.81%+229.95% 257M
Average -0.05%-1.13%+10.25%+44.13% 2.58B
Weighted average by Cap. +1.29%-0.04%+5.00%-7.38%

Financials

2024 2025
Net sales 588K 513K 475K 438K 826K 56.43M 841K 5.66M 2.22M 27.63M 2.21M 2.16M 95.15M 461K 403K 373K 344K 649K 44.32M 660K 4.45M 1.74M 21.7M 1.73M 1.7M 74.73M
Net income -2.38M -2.08M -1.92M -1.78M -3.34M -229M -3.4M -22.92M -8.99M -112M -8.94M -8.74M -385M -10.6M -9.27M -8.57M -7.91M -14.9M -1.02B -15.17M -102M -40.08M -499M -39.83M -38.95M -1.72B
Net Debt 1.42M 1.24M 1.15M 1.06M 2M 137M 2.04M 13.72M 5.38M 67M 5.35M 5.23M 231M -1.14M -993K -918K -848K -1.6M -109M -1.63M -10.95M -4.29M -53.44M -4.27M -4.17M -184M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-